Repetitive Magnetic Transcranial Stimulation (rTMS) in the Treatment of Generalized Anxiety Disorder (GAD)

Inclusion Criteria:

• The subject is male or female outpatients age 18 to 65 years, inclusive

• The subject meets DSM-IV criteria for Generalized Anxiety Disorder as determined bythe MINI.

• Sexually active female patients of childbearing potential must be practicing at leastone or more the following methods of contraception during the study: intrauterinedevice (IUD), barrier method in combination with a spermicide, oral/hormonalcontraception or abstinence. Female patients of childbearing potential must have anegative pregnancy test prior to receiving study drug.

• Written informed consent must be obtained from the subject prior to studyparticipation.

• The subject is in good medical health or with chronic medical conditions which arecurrently stable.

• No current abuse of alcohol or other substance.

• The subject has a total score of 20 or more on the SIGH-A at screening.

• The subject has a Clinical Global Impression (CGI) Severity score of 4 or more atscreening.

Exclusion Criteria:

• The subject meets DSM-IV criteria for an Axis I diagnosis (other than GAD) as theprimary diagnosis (i.e., schizophrenia, mood disorder, psychosis, anorexia nervosa) asdetermined by the MINI.

• The subject is clinically judged by the investigator to be at risk for suicide or isacutely suicidal as objectively measured by the MINI and MSE.

• The subject is clinically judged by the investigator to be at risk for homicide or isacutely homicidal as objectively measured by the MINI and MSE.

• The subject has a psychiatric condition that would require inpatient, or partialpsychiatric hospitalization.

• Seizure disorders.

• Significant history of medical disease (i.e. cardiovascular, hepatic (e.g. cirrhosis,hepatitis B or C) renal, gynecological, musculoskeletal, neurological,gastrointestinal, metabolic, hematological, endocrine, cancer with a metastaticpotential or progressive neurological disorders) which could impair reliableparticipation in the trial or necessitate the use of medication not allowed by thisprotocol.

• The subject is pregnant, planning to become pregnant, or nursing. If a subject becomespregnant, she will be discontinued immediately and followed appropriately.

• Concomitant therapy with another investigational drug, or participation in aninvestigational drug study within one month prior to entering this study.

• Current psychotherapeutic treatment except for treatment with Specific ReuptakeInhibitor (SSRIs) medications which include: Fluoxetine (Prozac), Paroxetine (Paxil),Sertraline (Zoloft), Luvox (Fluvoxamine), and Citalopram. Potential subjects mayremain on one of the SSRI medications provided that he or she has been on a stabledose for at least 4 weeks prior to entering this study; this dose remains stablethroughout the remainder of this study; and it can be determined that this medicationis not exacerbating the anxiety symptoms.

• History of poor compliance or in the Investigator's judgment patients any subjectwhose treatment as an outpatient would be clinically contraindicated

• The subject has attempted suicide one or more times within the past twelve months

• The subject has a Structured Hamilton Depression Rating Scale (SIGH-D) score above 38which suggests a moderate to severe clinical level of depressive symptoms